Dear Business Partners & Customers,To accommodate our growing business, Luye Life Sciences Group Shanghai Office will be relocated from Building 12, Shanghai Business Park III, No.1036 Tianlin Roa...
Luye Pharma Group announced that the marketing authorization application for the company’s in-house developed Class 1 new drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has be...
Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD). With the end of proc...
Luye Pharma Group announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection), developed by the Group’s holding subsidiary Boan Biotech, has received marketing authorization from Ch...
GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled‘Design and synthesis of novel GalNAc linker moie...
Luye Pharma Group announced that a research paper on LY-CovMab, an innovative antibody developed by Boan Biotech, a holding subsidiary of the Group, has been published in Communications Biology, a sub...
Luye Pharma Group held a launch conference on March 27, 2021 to officially announce the launch of a new drug Rykindo® (Risperidone Microspheres for Injection (II)) in China.Rykindo® is an extended rel...
Luye Pharma Group today announced that the Group’s Class 1 new chemical entity (NCE) product Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has met the predefined endpoints in a ph...
Luye Pharma Group announced today that China’s National Medical Products Administration (NMPA) has approved the company’s independently developed Risperidone Microspheres for Injection (II...
Lung cancer is the malignancy with the highest morbidity and mortality worldwide. As one of the common histological types of Non-Small-Cell Lung Cancer (NSCLC), the treatment of advanced squamous cell...
TOP